SCHEMBL5359136

SCHEMBL5359136

COc1c(O)ccc(C=C2C(=O)Nc3ccc(Br)c(C)c32)c1[N+](=O)[O-]

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
ALDH1A1 P00352 2/20 0.41
LMNA P02545 2/20 0.41
POLB P06746 2/20 0.41
PKM P14618 2/20 0.41
APAF1 O14727 1/20 0.41
GAA P10253 1/20 0.41
CASP7 P55210 1/20 0.41
CASP9 P55211 1/20 0.41
CASP6 P55212 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MDM2 Q00987 1/20 0.39
LRRK2 Q5S007 3/20 0.37
HPGD P15428 2/20 0.37
KDM4E B2RXH2 1/20 0.37
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5367921 0.80 NOX4 (0.49) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL14519136 0.78 MDM2 (0.57) MDM2LRRK2NOX4
SCHEMBL5374069 0.78 MAPT (0.47) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL5369742 0.78 MAP3K7 (0.45) MAPTMEN1KMT2ALMNAPOLB
SCHEMBL5369354 0.78 MAP3K7 (0.54) MAPTMEN1KMT2ALMNAPOLB
SCHEMBL5357671 0.77 LRRK2 (0.51) MAPTALDH1A1MDM2LRRK2CDK2
SCHEMBL5361625 0.77 MDM2 (0.53) MDM2LRRK2GSK3BPDPK1
SCHEMBL5366021 0.77 KDM1A (0.53) MAPTMEN1KMT2AALDH1A1POLB
SCHEMBL5369985 0.77 MAPT (0.41) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL7136914 0.76 PDPK1 (0.39) MAPTALDH1A1GAAKDM4EGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MAPT 3048/4885MEN1 3855/4885KMT2A 4060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.